Epidemiology and risk factors for oesophageal adenocarcinoma

Lepage, Côme; Drouillard, Antoine; Jouve, Jean-Louis; Faivre, Jean

doi:10.1016/j.dld.2012.12.020

Cited by 60 publications

(46 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, the consumption of alcohol and cigarettes occurs more frequently in males, as compared with in females in China (39,40). Although the present study did not examine whether alcohol and cigarette consumption were risk factors for ESCC, as investigated in previous studies (41,42), the results demonstrated that the consumption of alcohol was significantly associated with poor OS in ESCC.…”

Section: Discussioncontrasting

confidence: 45%

Prognostic value of MLH1 promoter methylation in male patients with esophageal squamous cell carcinoma

Chen

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. The DNA mismatch repair (MMR) gene MutL homolog 1 (MLH1) is critical for the maintenance of genomic integrity. Methylation of the MLH1 gene promoter was identified as a prognostic marker for numerous types of cancer including glioblastoma, colorectal, ovarian and gastric cancer. The present study aimed to determine whether MLH1 promoter methylation was associated with survival in male patients with esophageal squamous cell carcinoma (ESCC). Formalin-fixed, paraffin-embedded ESCC tissues were collected from 87 male patients. MLH1 promoter methylation was assessed using the methylation-specific polymerase chain reaction approach. Kaplan-Meier survival curves and log-rank tests were used to evaluate the association between MLH1 promoter methylation and overall survival (OS) in patients with ESCC. Cox regression analysis was used to obtain crude and multivariate hazard ratios (HR), and 95% confidence intervals (CI). The present study revealed that MLH1 promoter methylation was observed in 53/87 (60.9%) of male patients with ESCC. Kaplan-Meier survival analysis demonstrated that MLH1 promoter hypermethylation was significantly associated with poorer prognosis in patients with ESCC (P=0.048). Multivariate survival analysis revealed that MLH1 promoter hypermethylation was an independent predictor of poor OS in male patients with ESCC (HR=1.716; 95% CI=1.008-2.921). Therefore, MLH1 promoter hypermethylation may be a predictor of prognosis in male patients with ESCC.

show abstract

Section: Discussioncontrasting

confidence: 45%

Prognostic value of MLH1 promoter methylation in male patients with esophageal squamous cell carcinoma

Chen

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…The incidence of esophageal adenocarcinoma (EAC) has increased sixfold in the last 30 yr (Lepage et al 2013). The majority of patients present with advanced disease, and the overall survival is <15% despite advances in multimodal therapy (Jemal et al 2011;Masclee et al 2014).…”

mentioning

confidence: 99%

A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy

et al. 2017

View full text Add to dashboard Cite

The scientific community has avoided using tissue samples from patients that have been exposed to systemic chemotherapy to infer the genomic landscape of a given cancer. Esophageal adenocarcinoma is a heterogeneous, chemoresistant tumor for which the availability and size of pretreatment endoscopic samples are limiting. This study compares whole-genome sequencing data obtained from chemo-naive and chemo-treated samples. The quality of whole-genomic sequencing data is comparable across all samples regardless of chemotherapy status. Inclusion of samples collected post-chemotherapy increased the proportion of late-stage tumors. When comparing matched pre-and post-chemotherapy samples from 10 cases, the mutational signatures, copy number, and SNV mutational profiles reflect the expected heterogeneity in this disease. Analysis of SNVs in relation to allele-specific copy-number changes pinpoints the common ancestor to a point prior to chemotherapy. For cases in which pre-and post-chemotherapy samples do show substantial differences, the timing of the divergence is near-synchronous with endoreduplication. Comparison across a large prospective cohort (62 treatment-naive, 58 chemotherapy-treated samples) reveals no significant differences in the overall mutation rate, mutation signatures, specific recurrent point mutations, or copy-number events in respect to chemotherapy status. In conclusion, whole-genome sequencing of samples obtained following neoadjuvant chemotherapy is representative of the genomic landscape of esophageal adenocarcinoma. Excluding these samples reduces the material available for cataloging and introduces a bias toward the earlier stages of cancer.

show abstract

“…1 BO is an important risk factor for the development of OAC via a stepwise pathway of lowand high-grade dysplasia. 1,2 It is estimated that the risk of OAC is increased by approximately 30-125-fold in persons with BO. 3 Endoscopic surveillance for OAC among patients with BO is therefore recommended.…”

Section: Discussionmentioning

confidence: 99%

The incidence of Barrett's oesophagus and oesophageal adenocarcinoma in the United Kingdom and the Netherlands is levelling off

Masclee

Coloma

Wilde

et al. 2014

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Epidemiology and risk factors for oesophageal adenocarcinoma

Cited by 60 publications

References 57 publications

Prognostic value of MLH1 promoter methylation in male patients with esophageal squamous cell carcinoma

Prognostic value of MLH1 promoter methylation in male patients with esophageal squamous cell carcinoma

A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy

The incidence of Barrett's oesophagus and oesophageal adenocarcinoma in the United Kingdom and the Netherlands is levelling off

Contact Info

Product

Resources

About